Document 0201
 DOCN  M9590201
 TI    Ganciclovir administration practices in hospitals, ambulatory care
       settings, and in the home.
 DT    9509
 AU    Dobson PM; Groombridge C; MacDonald J; Dagg S; Immunology & Infectious
       Diseases Unit, John Hunter Hospital,; Hunter Region Mail Center, NSW.
 SO    Annu Conf Australas Soc HIV Med. 1994 Nov 3-6;6:68 (unnumbered
       abstract). Unique Identifier : AIDSLINE ASHM6/95291898
 AB    Ganciclovir sodium (Cymevene) is an antiviral drug frequently used in
       the management of CMV infections which are a common cause of morbidity
       in patients with AIDS. Treatment in this group often consists of daily
       intravenous (IV) infusions of ganciclovir for prolonged periods of time
       (weeks to years). Because of the duration of treatment, patients and
       their carers are often taught to administer these infusions in the home.
       The manufacturer of Cymevene recommends that cytotoxic precautions be
       utilised in the handling and disposal of the drug. Discussions with a
       number of units using IV ganciclovir revealed a marked variation in
       administration practices. This survey of hospitals and ambulatory
       clinics aims to define the range in variation of practices. The
       questionnaire will address the availability and utilisation of
       protective equipment in the unit and the home setting; education
       relating to ganciclovir usage provided to health care
       workers/patients/carers; disposal of equipment used in the
       administration of ganciclovir; disposal of excreta of patients receiving
       ganciclovir; management of ganciclovir spills/exposures; and transport
       of ganciclovir-associated waste. Results of this study will be
       presented, and should provide a sound basis to encourage the adoption of
       universal practices.
 DE    *Ambulatory Care  AIDS-Related Opportunistic Infections/*DRUG THERAPY
       Caregivers/EDUCATION  Cytomegalovirus Infections/*DRUG THERAPY
       Ganciclovir/*ADMINISTRATION & DOSAGE/ADVERSE EFFECTS  *Home Care
       Services  Human  Infusions, Intravenous  *Patient Admission  Universal
       Precautions  MEETING ABSTRACT

       SOURCE: National Library of Medicine.  NOTICE: This material may be
       protected by Copyright Law (Title 17, U.S.Code).